{"id":742100,"date":"2011-08-23T07:00:00","date_gmt":"2011-08-23T07:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-appoints-richard-r-deluca-jr-as-president-merck-animal-health\/"},"modified":"2026-08-10T13:01:17","modified_gmt":"2026-08-10T17:01:17","slug":"merck-appoints-richard-r-deluca-jr-as-president-merck-animal-health","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-appoints-richard-r-deluca-jr-as-president-merck-animal-health\/","title":{"rendered":"Merck Appoints Richard R. DeLuca Jr. as President, Merck Animal Health"},"content":{"rendered":"<p class=\"bwalignc\">       Former Becton Dickinson and Wyeth Executive Joins Merck     <\/p>\n<p>WHITEHOUSE STATION, N.J.&#8211;(BUSINESS WIRE)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,        today announced the appointment of Richard R. DeLuca Jr. as executive        vice president and president, Merck Animal Health, effective September        15, 2011. DeLuca, 48, will report to Kenneth C. Frazier, Merck\u2019s        president and chief executive officer, and will serve on the company\u2019s        Executive Committee. He will succeed Raul Kohan, who has decided to        retire from the company. Kohan will remain with the company until the        end of the year, reporting to Frazier, to ensure a smooth transition.     <\/p>\n<p>       As leader of Merck Animal Health, DeLuca will leverage the division&#8217;s        strong product portfolio and customer focus to capitalize on new growth        opportunities, including expanding the business in emerging markets. The        unit offers veterinarians, farmers, pet owners and governments a broad        range of veterinary pharmaceuticals, vaccines and health management        solutions and services in more than 50 countries, while its products are        available in some 150 markets.     <\/p>\n<p>       \u201cMerck Animal Health, one of the largest and most profitable animal        health businesses in the world, is an integral part of Merck. We believe        the business is well positioned in a number of fast-growing segments        within the global animal health market,&#8221; said Frazier. &#8220;We are delighted        to welcome Rick DeLuca as the new leader of our Animal Health division,        with his experience leading and growing international animal health        businesses. While Merck Animal Health already has a considerable        presence around the world, further global expansion of the business        represents a significant long-term growth opportunity for us.     <\/p>\n<p>       &#8220;I also want to thank Raul for his steady leadership in bringing        together Intervet and Schering-Plough Animal Health and maintaining the        unit&#8217;s strong performance through the merger and integration of Merck        and Schering-Plough to create a highly competitive and valuable animal        health franchise,&#8221; Frazier added. &#8220;Raul&#8217;s contributions to this        important part of our business and his development of an experienced        senior leadership team, created a firm foundation upon which Rick can        build going forward. We appreciate Raul&#8217;s dedication to ensuring a        smooth leadership transition in the coming months before he retires from        Merck.&#8221;     <\/p>\n<p>       \u201cThis is a wonderful time to join Merck, with its commitment to growing        its animal health business,\u201d said DeLuca. \u201cI look forward to working        with the talented managers and employees in ensuring that the division        is a best-in-class global animal health leader.&#8221;     <\/p>\n<p>       DeLuca served as chief financial officer of BD Biosciences since 2010.        Prior to that, he was president of Wyeth&#8217;s Fort Dodge Animal Health        division since 2007. While at Wyeth, DeLuca led a global team across all        functions of the business unit with worldwide revenues of over $1        billion.     <\/p>\n<p>       Prior to leading the Fort Dodge Animal Health division, DeLuca was chief        operating officer of Fort Dodge from 2006 to 2007, where he oversaw all        sales and marketing activities and implemented growth strategies        internationally. He also served as the division&#8217;s executive vice        president and chief financial officer from 2002 to 2006, where he was        responsible for all finance and administration, information systems and        product supply planning and logistics activities. Prior to that, DeLuca        held a variety of managerial roles at Wyeth and elsewhere since 1982.     <\/p>\n<p>       DeLuca received his bachelor&#8217;s degree in business administration from        Widener University in Chester, Pennsylvania.     <\/p>\n<p>       <b>About Merck<\/b>     <\/p>\n<p>       Today&#8217;s Merck is a global healthcare leader working to help the world be        well. Merck is known as MAD outside the United States and Canada.        Through our prescription medicines, vaccines, biologic therapies, and        consumer care and animal health products, we work with customers and        operate in more than 140 countries to deliver innovative health        solutions. We also demonstrate our commitment to increasing access to        healthcare through far-reaching policies, programs and partnerships. For        more information, visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com&amp;esheet=6837984&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=1&amp;md5=34a11b215ba6d017ed32cbae6cf1fd79\">www.merck.com<\/a>.     <\/p>\n<p>       <b>Forward-Looking Statement<\/b>     <\/p>\n<p>       This news release includes \u201cforward-looking statements\u201d within the        meaning of the safe harbor provisions of the United States Private        Securities Litigation Reform Act of 1995. Such statements may include,        but are not limited to, statements about the benefits of the merger        between Merck and Schering-Plough, including future financial and        operating results, the combined company\u2019s plans, objectives,        expectations and intentions and other statements that are not historical        facts. Such statements are based upon the current beliefs and        expectations of Merck\u2019s management and are subject to significant risks        and uncertainties. Actual results may differ from those set forth in the        forward-looking statements.     <\/p>\n<p>       The following factors, among others, could cause actual results to        differ from those set forth in the forward-looking statements: the        possibility that the expected synergies from the merger of Merck and        Schering-Plough will not be realized, or will not be realized within the        expected time period; the impact of pharmaceutical industry regulation        and health care legislation; the risk that the businesses will not be        integrated successfully; disruption from the merger making it more        difficult to maintain business and operational relationships; Merck\u2019s        ability to accurately predict future market conditions; dependence on        the effectiveness of Merck\u2019s patents and other protections for        innovative products; the risk of new and changing regulation and health        policies in the U.S. and internationally and the exposure to litigation        and\/or regulatory actions.     <\/p>\n<p>       Merck undertakes no obligation to publicly update any forward-looking        statement, whether as a result of new information, future events or        otherwise. Additional factors that could cause results to differ        materially from those described in the forward-looking statements can be        found in Merck\u2019s 2010 Annual Report on Form 10-K and the company\u2019s other        filings with the Securities and Exchange Commission (SEC) available at        the SEC\u2019s Internet site (<a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=6837984&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=2&amp;md5=e0ddd88c3b69ad23a34e7f6641ec73cc\">www.sec.gov<\/a>).     <\/p>\n<p class=\"bwalignc\">\n<p><p>       Merck<br \/>Media Contacts:<br \/>Ron Rogers, 908-423-6449<br \/>or<br \/>Investor        Contacts:<br \/>Carol Ferguson, 908-423-4465     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of Richard R. DeLuca Jr. as executive vice president and president, Merck Animal Health, effective September 15, 2011. DeLuca, 48, will report to Kenneth C. Frazier, Merck\u2019s president and chief executive officer, and will serve on the company\u2019s Executive Committee. He will succeed Raul Kohan, who has decided to retire from the company. Kohan will remain with the company until the end of the year, reporting to Frazier, to ensure a smooth transition. As leader of Merck Animal Health, DeLuca will leverage the division&#8217;s strong product portfolio and customer focus to capitalize on new growth opportunities, including expanding the business in emerging markets. The unit offers veterinarians, farmers, pet owners and governments a broad range of veterinary pharmaceuticals, vaccines and health management solutions and services in more than 50 countries, while its products are available in some<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742100","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Appoints Richard R. DeLuca Jr. as President, Merck Animal Health - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-appoints-richard-r-deluca-jr-as-president-merck-animal-health\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Appoints Richard R. DeLuca Jr. as President, Merck Animal Health - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of Richard R. DeLuca Jr. as executive vice president and president, Merck Animal Health, effective September 15, 2011. DeLuca, 48, will report to Kenneth C. Frazier, Merck\u2019s president and chief executive officer, and will serve on the company\u2019s Executive Committee. He will succeed Raul Kohan, who has decided to retire from the company. Kohan will remain with the company until the end of the year, reporting to Frazier, to ensure a smooth transition. As leader of Merck Animal Health, DeLuca will leverage the division&#039;s strong product portfolio and customer focus to capitalize on new growth opportunities, including expanding the business in emerging markets. The unit offers veterinarians, farmers, pet owners and governments a broad range of veterinary pharmaceuticals, vaccines and health management solutions and services in more than 50 countries, while its products are available in some\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-appoints-richard-r-deluca-jr-as-president-merck-animal-health\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-appoints-richard-r-deluca-jr-as-president-merck-animal-health\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-appoints-richard-r-deluca-jr-as-president-merck-animal-health\\\/\",\"name\":\"Merck Appoints Richard R. DeLuca Jr. as President, Merck Animal Health - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2011-08-23T07:00:00+00:00\",\"dateModified\":\"2026-08-10T17:01:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-appoints-richard-r-deluca-jr-as-president-merck-animal-health\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-appoints-richard-r-deluca-jr-as-president-merck-animal-health\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-appoints-richard-r-deluca-jr-as-president-merck-animal-health\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Appoints Richard R. DeLuca Jr. as President, Merck Animal Health\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Appoints Richard R. DeLuca Jr. as President, Merck Animal Health - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-appoints-richard-r-deluca-jr-as-president-merck-animal-health\/","og_locale":"en_US","og_type":"article","og_title":"Merck Appoints Richard R. DeLuca Jr. as President, Merck Animal Health - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of Richard R. DeLuca Jr. as executive vice president and president, Merck Animal Health, effective September 15, 2011. DeLuca, 48, will report to Kenneth C. Frazier, Merck\u2019s president and chief executive officer, and will serve on the company\u2019s Executive Committee. He will succeed Raul Kohan, who has decided to retire from the company. Kohan will remain with the company until the end of the year, reporting to Frazier, to ensure a smooth transition. As leader of Merck Animal Health, DeLuca will leverage the division's strong product portfolio and customer focus to capitalize on new growth opportunities, including expanding the business in emerging markets. The unit offers veterinarians, farmers, pet owners and governments a broad range of veterinary pharmaceuticals, vaccines and health management solutions and services in more than 50 countries, while its products are available in some","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-appoints-richard-r-deluca-jr-as-president-merck-animal-health\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:17+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-appoints-richard-r-deluca-jr-as-president-merck-animal-health\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-appoints-richard-r-deluca-jr-as-president-merck-animal-health\/","name":"Merck Appoints Richard R. DeLuca Jr. as President, Merck Animal Health - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2011-08-23T07:00:00+00:00","dateModified":"2026-08-10T17:01:17+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-appoints-richard-r-deluca-jr-as-president-merck-animal-health\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-appoints-richard-r-deluca-jr-as-president-merck-animal-health\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-appoints-richard-r-deluca-jr-as-president-merck-animal-health\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Appoints Richard R. DeLuca Jr. as President, Merck Animal Health"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"0089246d-e3f6-40a3-b735-bf8f5fed969a","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Appoints-Richard-R-DeLuca-Jr-as-President-Merck-Animal-Health-2011.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742100\/revisions"}],"predecessor-version":[{"id":3679236,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742100\/revisions\/3679236"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742100"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}